EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

The α2‐Subunit Preferring GABA Positive Allosteric Modulator, N‐Desmethyl‐Clobazam in Peripheral Neuropathic Pain Patients: Results of a Phase IIa Randomised Placebo‐Controlled Ascending Dose Study

M Besson, A Matthey, Y Daali, A Ramsahye, C Samer, J Desmeules, F Curtin

European Journal of Pain · 2026

DOI: 10.1002/ejp.70413 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Pain, 2026. Verfasst von M Besson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology and Toxicology, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland. Hauptthemen laut MEDLINE: Neuralgia, Clobazam, Analgesics. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss innovation agency (Innosuisse), Innosuisse - Schweizerische Agentur für Innovationsförderung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

N‐desmethyl clobazam (NDMC), an α2‐preferring‐α1‐sparing‐GABA A modulator, was promising in preclinical models and Phase I studies, demonstrating antihyperalgesic properties without associated sedation. This Phase IIa trial aimed at exploring the effect of NDMC in peripheral neuropathic pain (NP) patients.

Method

Randomised, ascending doses, double‐blind, placebo‐controlled study, evaluating 40, 60, 120 mg of NDMC. Primary outcome was the change in weekly average daily pain (WADP) on a Numerical Rating Scale (NRS) from baseline (V1) to the end of the study (V7). Secondary outcomes included sedation (subjective NRS), quality of life (SF36), global and patient impression of change (CGI, PCGI). PK and safety data were collected. The study was prematurely terminated due to recruitment challenges related to the COVID‐19 pandemic.

Results

Thirty‐three out of the planned 76 patients were enrolled. The mean reduction in WADP from V1 to V7 was −1.53 points for placebo and −1.99 across all NDMC doses (delta = 0.46, p = 0.47). When analysed according to NDMC plasma concentrations, the mean WADP reduction was 1.53 (SD 1.58) for placebo 1.78 (SD 1.79) for NDMC < 1000 ng/mL, and 2.40 (SD 1.46) for NDMC ≥ 1000 ng/mL. The prevalence of 30% pain reduction was 38.5% (placebo) and 83.3% (NDMC ≥ 1000 ng/mL). Logistic regression analysis indicated that NDMC ≥ 1000 ng/nL was predictive of a 30% pain reduction (odds ratio = 12.5, p = 0.04). NDMC was well tolerated.

Conclusion

Despite being underpowered, this study revealed a consistent exposure–response relationship along with a favourable safety profile for NDMC in patients with NP. Trial Registration ClinicalTrial.gov (NCT03375034); kofam.ch (SNCTP000003517). Significance Statement This work presenting the Phase II data of the new antihyperalgesic compound, N‐Desmethyl‐Clobazam (NDMC) in peripheral neuropathic pain patients support further investigation into the role in modulating GABAergic pathways as a potential therapeutic target for neuropathic pain. This objective is particularly relevant given the limited efficacy of standard pharmacological treatments for neuropathic pain, which often requires a multimodal approach targeting the multiple pathways involved in pain pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuralgiaClobazamAnalgesicsHumansFemaleMaleDouble-Blind MethodMiddle AgedAgedDose-Response Relationship, DrugAdultPain MeasurementTreatment OutcomeQuality of Life

Substanzen

ClobazamAnalgesics

Autor:innen und Institutionen

  • Division of Clinical Pharmacology and Toxicology, Department of Acute Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Anesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, Geneva, Switzerland.

Förderung

  • Swiss innovation agency (Innosuisse)
  • Innosuisse - Schweizerische Agentur für Innovationsförderung

Zitieren

APA

Besson, M., Matthey, A., Daali, Y., Ramsahye, A., Samer, C., Desmeules, J., & Curtin, F. (2026). The α2‐Subunit Preferring GABA Positive Allosteric Modulator, N‐Desmethyl‐Clobazam in Peripheral Neuropathic Pain Patients: Results of a Phase IIa Randomised Placebo‐Controlled Ascending Dose Study. European Journal of Pain. https://doi.org/10.1002/ejp.70413

Vancouver

Besson M, Matthey A, Daali Y, Ramsahye A, Samer C, Desmeules J, et al. The α2‐Subunit Preferring GABA Positive Allosteric Modulator, N‐Desmethyl‐Clobazam in Peripheral Neuropathic Pain Patients: Results of a Phase IIa Randomised Placebo‐Controlled Ascending Dose Study. European Journal of Pain. 2026. doi:10.1002/ejp.70413

BibTeX
@article{Besson2026,
  author = {Besson, M and Matthey, A and Daali, Y and Ramsahye, A and Samer, C and Desmeules, J and Curtin, F},
  title = {The α2‐Subunit Preferring GABA Positive Allosteric Modulator, N‐Desmethyl‐Clobazam in Peripheral Neuropathic Pain Patients: Results of a Phase IIa Randomised Placebo‐Controlled Ascending Dose Study},
  journal = {European Journal of Pain},
  year = {2026},
  doi = {10.1002/ejp.70413}
}
Kostenlos starten →